Teva was first to file for generic ADENOSCAN, making the product eligible for 180 days of marketing exclusivity.
Teva Pharmaceutical Industries Ltd. (NYSE: TEVA; TASE: TEVA) today announced the launch of the generic equivalent to ADENOSCAN (adenosine injection) in the US. Teva was first to file, making the product eligible for 180 days of marketing exclusivity. ADENOSCAN is supplied as 20 mL and 30 mL vials and is indicated as an adjunct to thallium-201 myocardial perfusion scintigraphy in patients unable to exercise adequately. Marketed by Astellas Pharma, ADENOSCAN had annual sales of about $65 million in the US, according to IMS data as of June 30, 2013.
Published by Globes [online], Israel business news - www.globes-online.com - on September 24, 2013
© Copyright of Globes Publisher Itonut (1983) Ltd. 2013